Response to Drs. de Grooth and Parienti.
Giganti MJ, Chew KW, Eron JJ, Smith DM, Currier JS, Hughes MD.
J Infect Dis. 2024 Feb 07. PMID: 38324658
Director of the Center for Biostatistics in AIDS Research
Biostatistics
Harvard T.H. Chan School of Public Health
Dr. Hughes' research program focuses on statistical methods related to the design and analysis of clinical trials and observational studies, particularly in the context of HIV research. He is well-known for his work on the development of methods for evaluating surrogate markers using meta-analysis of results from a number of clinical trials. An an important early application of this work was the assessment of the value of treatment-induced changes in CD4 cell counts and viral load as surrogate markers for the development of AIDS.
Dr. Hughes is the Principal Investigator of the Statistical and Data Management Center (SDMC) of the AIDS Clinical Trials Group (ACTG) funded by the National Institutes of Health. The ACTG undertakes numerous studies of interventions for the treatment of people infected with HIV, including co-infections such as tuberculosis and hepatitis B and C, both in the United States and internationally. He was previously the Principal Investigator for the SDMC of the Pediatric ACTG and has ongoing HIV research interests in the treatment of children infected with HIV, and the prevention of mother-to-child transmission of HIV. A particular focus of this work concerns studies evaluating the impact of prophylaxes for the prevention of transmission on restricted future treatment options for the mother due to viral resistance.
Dr. Hughes' statistical research is strongly motivated by problems encountered in his collaborative research. Ongoing research interests include the design and analysis of phase I/II clinical trials, and of bridging trials from one population to another population. One example concerns the design of studies that seek to identify the dose of a drug that maximizes the success of treatment (i.e. is both safe and effective) rather than just find the maximal tolerated dose. A second example involves the development of methodology for the design of dose-finding bridging studies in "special populations", such as infants or pregnant women, which are efficient in identifying a dose which minimizes the proportion of people who might be exposed to sub-therapeutic doses.
Another area of interest concerns statistical methods for the design and analysis of studies evaluating diagnostic and other biomarkers. For example, he is interested in the problem of comparing the performance of two biomarkers for determining when to start treatment in HIV-infected subjects, or when to change treatments. This work is motivated by the need to identify less expensive and more practically accessible technologies for addressing these questions in resource-limited countries.
Giganti MJ, Chew KW, Eron JJ, Smith DM, Currier JS, Hughes MD.
J Infect Dis. 2024 Feb 07. PMID: 38324658
Ngongondo M, Ritz J, Hughes MD, Matoga M, Hosseinipour MC.
PLOS Glob Public Health. 2024. 4(1):e0002648. PMID: 38175824
Omoz-Oarhe AE, Hughes MD, Yajing B, Short WR, Mngqibisa R, Cohn SE, Weinberg A, La Rosa A, Collier A, Samaneka W, Morroni C, Lockman S.
J Acquir Immune Defic Syndr. 2023 12 15. 94(5):461-467. PMID: 37820116
Coelho CH, Bloom N, Ramirez SI, Parikh UM, Heaps A, Sieg SF, Greninger A, Ritz J, Moser C, Eron JJ, Currier JS, Klekotka P, Wohl DA, Daar ES, Li J, Hughes MD, Chew KW, Smith DM, Crotty S.
bioRxiv. 2023 Nov 22. PMID: 38045374
Ramirez SI, Lopez PG, Faraji F, Parikh UM, Heaps A, Ritz J, Moser C, Eron JJ, Wohl DA, Currier JS, Daar ES, Greninger AL, Klekotka P, Grifoni A, Weiskopf D, Sette A, Peters B, Hughes MD, Chew KW, Smith DM, Crotty S.
bioRxiv. 2023 Oct 26. PMID: 37961119
Jagannathan P, Chew KW, Giganti MJ, Hughes MD, Moser C, Main MJ, Monk PD, Javan AC, Li JZ, Fletcher CV, McCarthy C, Wohl DA, Daar ES, Eron JJ, Currier JS, Singh U, Smith DM, Fischer W.
EClinicalMedicine. 2023 Nov. 65:102250. PMID: 37855026
Jilg N, Chew KW, Giganti MJ, Daar ES, Wohl DA, Javan AC, Kantor A, Moser C, Coombs RW, Neytman G, Hoover K, Jana A, Hart PA, Greninger AL, Szurgot B, Eron JJ, Currier JS, Hughes MD, Smith DM, Li JZ.
Clin Infect Dis. 2023 10 05. 77(7):941-949. PMID: 37279602
Gupta A, Hughes MD, Cruz JL, Avihingsanon A, Mwelase N, Severe P, Omoz-Oarhe A, Masheto G, Moran L, Benson CA, Chaisson RE, Swindells S.
Clin Infect Dis. 2023 Sep 28. PMID: 37768207
Krishnan S, Wu X, Kim S, McIntire K, Naini L, Hughes MD, Dawson R, Mave V, Gaikwad S, Sanchez J, Mendoza-Ticona A, Gonzales P, Comins K, Shenje J, Fontain SN, Omozoarhe A, Mohapi L, Lalloo UG, Garcia Ferreira AC, Mugah C, Harrington M, Shah NS, Hesseling AC, Churchyard G, Swindells S, Gupta A.
Clin Infect Dis. 2023 09 18. 77(6):892-900. PMID: 37227925
Phan T, Zitzmann C, Chew KW, Smith DM, Daar ES, Wohl DA, Eron JJ, Currier JS, Hughes MD, Choudhary MC, Deo R, Li JZ, Ribeiro RM, Ke R, Perelson AS.
bioRxiv. 2023 Sep 17. PMID: 37745410
April 27, 2017 — A positive HIV test result was once a near-certain death sentence, with more than 75% of people infected with the virus in the 1980s dying from AIDS. Today, HIV can be managed with antiretroviral…
October 21, 2010 -- An international study led by Shahin Lockman, assistant professor in immunology and infectious diseases at HSPH and a physician at Brigham and Women’s Hospital in Boston, has found that women who took single-dose nevirapine…